FDA解除对Intellia CRISPR药物试验的暂停。
FDA lifts hold on an Intellia CRISPR drug trial
生物技术与制药领域的最新动态
FDA lifts hold on an Intellia CRISPR drug trial
Roche, trailing in obesity, showcases new data for GLP-1 shot
An immune drug developer raises $50M to finance its eczema drug testing
China’s edge in early-stage drugmaking ‘likely to persist,’ Pitchbook says
Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time
Biotech investor Cormorant secures $150M for another SPAC deal
Express Scripts considering settlement in FTC insulin price lawsuit
The formula for biotech success in 2026: Confidence, resilience and funding
From detection to prevention: How sponsored testing can transform patient outcomes
The crucial role of raw material selection for success in cell therapy manufacturing
Sanofi to seek approval of touted eczema drug despite mixed results
Novo climbs higher on ‘strong’ Wegovy pill launch; Terns tweaks leukemia drug deal
Congress eyes tackling healthcare consolidation
Investors load Corxel with $287M for a ‘differentiated’ obesity pill
Bristol Myers buys into Janux’s ‘masked’ T cell engagers
FDA lays out new path to speed development of multiple myeloma drugs
BioMarin vets form Mendra to ‘modernize’ rare disease drug development
Corvus shares nearly triple on positive data for eczema pill
J&J eyes $100B in sales amid gains for cancer, immune drugs
Valneva to withdraw Chikungunya vaccine from US amid safety woes